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Abstract Enhanced intrarenal renin-angiotensin system
(RAS) is implicated in the development and progression of
renal injury. To investigate whether angiotensinogen (AGT)
expression is involved in glomerular RAS activity and
glomerular injury, we examined glomerular AGT expression
and its correlation with expression of other RAS components,
and levels of glomerular injury in samples from patients with
immunoglobulin A nephropathy (IgAN) (23) and minor
glomerular abnormalities (MGA) (8). Immunohistochemistry
showedthatAGTproteinwashighlyexpressedbyglomerular
endothelial cells (GEC) and mesangial cells in nephritic
glomeruli of IgAN compared with glomeruli of MGA. Levels
ofglomerularAGT protein werewellcorrelatedwith levelsof
glomerular angiotensin II (ang II), transforming growth
factor-β (TGF-β), α-smooth-muscle actin, glomerular cell
number, and glomerulosclerosis score but not with those of
glomerular angiotensin-converting enzyme and ang II type 1
receptor. Real-time polymerase chain reaction (RT-PCR)
and Western blot analyses using cultured human GEC
indicated that ang II upregulated AGT messenger ribonucleic
acid (mRNA) and protein expression in a dose- and time-
dependent manner. These data suggest that activated
glomerular AGT expression is likely involved in elevated
local ang II production and, thereby, may contribute to
increased TGF-β production and development of glomerular
injury in IgAN. Augmentation of GEC-AGT production with
ang II stimulation might drive further glomerular injury in a
positive-feedback loop.
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Introduction
Clinical and experimental studies have provided considerable
evidence for the roleofthe renin-angiotensin system(RAS) in
the development of hypertension and progression of renal
diseases [1, 2]. It is now established that all components of
the RAS are widely distributed in several tissues, including
the kidney [3, 4]. The local RAS in the kidney has several
pathophysiologic functions for not only regulating blood
pressure but also renal cell growth and production of
glomerulosclerosis, which is involved in the development
of renal fibrosis [5–8]. Indeed, previous studies have shown
beneficial effects of angiotensin-converting enzyme inhibitor
(ACEi) and/or angiotensin II (ang II) type 1 receptor (AT1R)
blocker (ARB) on various renal diseases in rats and humans,
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pressure [9–11].
IgA nephropathy(IgAN)isnowrecognizedtobethemost
common form of glomerulonephritis worldwide. It has been
reported that more than 30% of cases progress to end-stage
renal failure within 20 years [12, 13]. In pediatric IgAN,
glomerular lesion is characterized by an increased number
of mesangial cells (MC) and accumulation of mesangial
extracellular matrix (ECM), and this pathological change is
thought to be an early and active lesion for IgAN [14]. It is
reported that treatment with ACEi and/or ARB provides
antiproteinuric and renoprotective effects in normotensive
pediatric patients with IgAN, suggesting that intrarenal
action of ang II may play a critical role in the progression of
pediatric IgAN [15, 16]. Recently, a real-time polymerase
chain reaction (RT-PCR) study using isolated glomeruli
with IgAN revealed an increased expression of RAS
components such as renin, angiotensinogen (AGT), and
ACE, possibly followed by the production of ang II, an
effector molecule of RAS, suggesting that the glomerular
RAS activation might occur under this disease setting [17].
In this study, AGT messenger ribonucleic acid (mRNA)
levels were positively correlated with the mRNA expres-
sion of renin, ACE, and a fibrogenic cytokine transforming
growth factor-β (TGF-β). AGT is the sole substrate for the
RAS pathway, and it has been reported that AGT is present
within the kidney and ang II is produced locally, indepen-
dent of the circulating RAS [18]. Interestingly, the
increased expression of intrarenal AGT is directly involved
in the disease progression in several rat models of renal
injury [19–22]. However, little information is available
about protein expression in an RAS cascade from AGT to
ang II and the association between glomerular RAS
activation and pathological changes in childhood IgAN.
Therefore, in this study, the glomerular protein expres-
sion of RAS components such as AGT, ACE, ang II, and
AT1R, as well as their association with the index of
glomerular injury were examined to clarify the role of the
RAS cascade, especially that of AGT in glomerular lesions
of pediatric IgAN. Subsequently, we investigated the
amplification mechanism of glomerular AGT expression
leading to an increase of glomerular RAS activity using
cultured human glomerular endothelial cells (GEC).
Materials and methods
Kidney tissue
Renal tissues used for this study were obtained from 23
children with IgAN and eight with minor glomerular
abnormalities (MGA) by biopsy. Diagnosis of renal diseases
was made based on studies of tissue by light, electron,
and immunofluorescence microscopy according to the
classification of the World Health Organization (WHO)
[23]. This classification defined diffuse mesangial prolifer-
ation as >80% of glomeruli showing moderate or severe
mesangial cell proliferation, i.e. more than three cells per
peripheral mesangial area, and focal mesangial proliferation
as up to 80% of glomeruli showing the same changes
described above. IgAN was diagnosed as a mesangial
proliferative glomerulonephritis with predominant IgA de-
posit in the mesangium. Patients diagnosed with IgAN
showed diffuse mesangial proliferation (15) or focal
mesangial proliferation (8). Patients diagnosed with MGA
showed normal glomerular morphology and negative immu-
nofluorescence but had mild proteinuria or microscopic
hematuria. All subjects with other disorders, including
Henoch-Schönlein purpura, systemic lupus erythematosus,
and chronic liver disease, were excluded. The control tissue
(5) consisted of normal cortex taken from kidneys resected
for localized neoplasms. Blood pressure, serum creatinine,
and creatinine clearance were normal in all participants at the
time of biopsy. Patients had not been previously treated with
either ACEi, ARB, glucocorticosteroids, or immunosuppres-
sive agents. The study protocol was approved by the ethics
committee of the University of Tokushima Graduate School,
and written informed consent was obtained from all patients
and/or their parents in all cases. The clinical laboratory
parameters, including age, term from onset of urinary
abnormalities to renal biopsy, blood pressure, proteinuria,
hematuria index, serum creatinine, and 24-h creatinine
clearance were determined at the time of biopsy. Based on
examination of urine samples, the severity of hematuria was
classified as follows: 0, 0–5 erythrocytes/high-power field
(HPF); 1+, 5–30 erythrocytes/HPF; 2+, >30 erythrocytes/
HPF; 3+, macroscopic hematuria, as previously described
[24]. Clinical data are presented in Table 1.
Histological scoring of glomerular cell proliferation,
glomerulosclerosis, and tubulointerstitial changes
For light-microscopic examination, the biopsied tissues were
fixed in 10% buffered formalin and embedded in paraffin.
Paraffin sections (3 μm) were stained with periodic acid-
Schiff reagent. All glomeruli in each section (usually 10–26)
were coded and read by a blinded observer. The number of
cells in at least four equatorially cut glomeruli in each section
was counted, and the average number of cells was used as an
indicator of glomerular cell proliferation, as previously
described[25]. The glomerulosclerosis (GS) score was deter-
mined using a previously described method with a modifi-
cation [26]. The percentage of each glomerulus occupied by
mesangial ECM was estimated and assigned a code as
follows: 0, absent; 1+, 1–5%; 2+, 5–25%; 3+, 25–50%; 4+,
>50%; and the mean value per specimen was calculated [27].
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fields of the cortical interstitium in each section were
examined, as previously described [28]. In each field,
tubulointerstitial change, like tubular atrophy and interstitial
broadening, were graded as follows: 0, representing involve-
ment of <5%; 1+, involvement between 5 and 20%; 2+,
involvement between 20 and 40%; 3+, involvement of >40%.
Antibodies
Chicken IgY-rich fraction against highly purified full-length
human plasma AGT (anti-AGT antibody) was used for
immunohistochemistry [29]. Mouse monoclonal anti-ACE
antibody, rabbit polyclonal anti-ang II serum, and rabbit
polyclonal anti-AT1R antibody were purchased from
Chemicon International (Temecula, CA, USA), IgG corpo-
ration (Nashville, TN, USA) and Santa Cruz Biotechnology
(Santa Cruz, CA, USA), respectively. Mouse monoclonal
anti-α-smooth-muscle (α-SM) actin antibody (1A4) was
purchased from Sigma-Aldrich (St. Louis, MO, USA) and
was used to detect activated human MC. Rabbit polyclonal
anti-TGF-β antibody was a kind gift from Dr. Kawachi
(Niigata University, Niigata, Japan).
Immunohistochemistry
The glomerular expression of AGTor AT1R was detected by
an immunoperoxidase technique, as previously described
[27]. Briefly, the sections (3 μm) were incubated with the
primary antibodies overnight at 4°C. After rinsing, the
sections were incubated with either biotinylated anti-chicken
IgG (for AGT) (Vector Labs, Burlingame, CA, USA) or
biotinylated anti-rabbit IgG (for AT1R) (Vector Labs). After
rinsing, the sections were incubated with avidin-biotin-
peroxidase complex (ABC Elite; Vector Labs), followed by
3,3′-diaminobenzidine (Dojindo, Kumamoto, Japan). Each
section was counterstained with Mayer’s hematoxylin
(Wako, Tokyo, Japan), dehydrated, and coverslipped.
In double-staining experiments, 3-μm frozen sections
stained with chicken anti-AGT antibody, and fluorescein-
isothiocyanate (FITC)-labeled donkey anti-chicken IgG
antibody (Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) were further incubated with either mouse
anti-CD31 antibody (DAKO, Glostrup, Denmark), mouse
monoclonalanti-α-SMactinantibody(1A4),ormousemono-
clonal synaptopodin antibody (G1D4; Progen Biotechnik,
Heidelberg, Germany), followed by an appropriate tetra-
methylrhodamine-isothiocyanate (TRITC)-coupled donkey
anti-mouse antibody (Jackson Immuno-Research Laborato-
ries). Indirect immunofluorescent staining was performed
using the following primary antibodies: anti-ACE antibody,
anti-ang II antiserum, anti-α-SM actin antibody, and anti-
TGF-β antibody. FITC-labeled donkey anti-rabbit IgG anti-
body, donkey anti-mouse IgG, and TRITC-labeled donkey
anti-mouse IgG (Jackson ImmunoResearch Laboratories)
were used as the secondary antibodies. Frozen sections were
incubated with primary antibodies for 1 h, and then secondary
antibodies, appropriately. To evaluate the level of glomerular
staining with each antibody, we performed semiquantitative
analysis. The immunostaining of AGTwas graded as follows:
0, very weak or absent capillary or mesangial staining; 1+,
weak capillary staining with 1–25% focally increased capil-
lary staining; 2+, 25–50% of glomerular tuft demonstrating
strong capillary and mesangial staining; 3+, 50–75% of
glomerular tuft demonstrating strong capillary and mesangial
staining; 4+,75% ormoreofthe glomerulartuftdemonstrated
strong capillary and mesangial staining, as previously
described [25]. The immunostaining of ACE, ang II, AT1R,
TGF-β,a n dα-SM actin was graded as follows: 0, no
staining; 1+, weak staining; 2+, mild staining; 3+, moderate
staining; 4+, marked staining. At least four equatorially
sectioned glomeruli in each section were evaluated blindly
by two separate investigators. The individual immuno-
staining score was determined by calculating the average
value per single glomerulus [27].
Cell culture
Cultured human GEC derived from normal human kidneys
were purchased from Cell System (Kirkland, WA, USA).
Table 1 Clinical data of
patients
MGA minor glomerular
abnormalities, IgAN immuno-
globulin A nephropathy
Data are means ± standard
deviation
* P<0.01 vs MGA
MGA IgAN
Number 8 23
Age (years) 13.1±1.9 13.0±3.1
Term from onset of urinary abnormalities to
renal biopsy (years)
1.5±1.2 0.9±0.7
Systolic/diastolic blood pressure (mmHg) 112.1±9.5/62.6±7.5 111.0±10.4/61.3±7.9
Proteinuria (g/day) 0.07±0.04 0.37±0.26*
Hematuria index 0.93±0.37 1.89±0.70*
Serum creatine (mg/dl) 0.54±0.14 0.54±0.15
24-h creatine clearance (ml/min per 1.73 m
2) 100.5±23.5 103.8±29.9
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type 1 collagen, as described previously [30]. Human GEC
were used at the sixth to eighth passage in our experiments.
At about 70–80% confluency, GEC growth was arrested by
incubation for 48 h in serum-free medium and then treated
with ang II at increasing concentrations (0, 10
−11,1 0
−9,
10
−7 M) for 3–12 h to detect mRNA or protein, respec-
tively. In addition, a time-course study was undertaken to
assess changes in AGT mRNA expression at 0, 1, 3, 6, 12,
and 24 h and protein expression at 0, 6, 12, and 24 h with
10
−7 M ang II-treated GEC. Cells were harvested for RNA
extraction and total cell extract preparation.
Western blot
Human GEC cultures were dissolved in radioimmunopre-
cipitation assay (RIPA) buffer. Protein samples (25 μg)
were separated by 12.5% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) and transferred
onto nitrocellulose membranes (Amersham Bioscience,
Piscataway, NJ, USA). The membranes were probed with
anti-AGT antibody (1:1,000) and then incubated with a
horseradish peroxidase-conjugated rabbit anti-chicken/
turkey IgG (H+L) (1:2,000; Zymed Laboratories, San
Francisco, CA, USA). Equivalent protein loading for each
lane was confirmed by stripping and reblotting each
membrane for β-actin (1:10,000; Sigma-Aldrich). Immu-
noreactive proteins were detected with an enhanced
chemiluminescence detection system (Amersham Corp.,
Arlington Heights, IL, USA). The antibodies were tested
on human purified AGT (Calbiochem, Merck, Darmstadt,
Germany) as control, where two bands between 50 and
60 kD were detected [31]. Bands were quantitated by
ImageJ 1.33u (National Institute of Health), and the fold
expression was indicated as the relative protein level.
RT-PCR
Total RNA (500 ng) extracted from human cell cultures was
reverse transcripted using the SYBR ExScript RT-PCR Kit
(TaKaRa, Kyoto, Japan). The complementary DNAs
(cDNAs) were amplified by RT-PCR with primers for
human AGT (forward 5′-TCTCCCCGGACCATCCA-3′
and reverse 5′-TGCTCAATTTTTGCAGGTTCAG-3′) and
glyceraldehyde-3 phosphate dehydrogenase (G3PDH)
(forward 5′-GAAGGTGAAGGTCGGAGT-3′ and reverse
5′-TGGCAACAATATCCACTTTACCA-3′) as an internal
control, using iCycler Thermal Cycler (BioRad, Hercules,
CA, USA) [17, 32]. Melting curve analysis and PAGE
confirmed the specificity of the amplification products.
Semiquantification data were analyzed with iCycler analysis
software and expressed as the ratio between starting the
quantity mean of the target and the G3PDH gene.
Statistical analysis
Results are presented as means ± standard deviation (SD).
StatView (SAS institute) was used for statistical analyses.
Between-group differences were assessed by the unpaired
t test. The correlation of two variations was evaluated using
Pearson’s or Spearman’s correlation coefficients. Western
blot and RT-PCR analyses were performed at least three
times, and representative results are shown in the figures.
The mRNA expression or protein synthesis of AGT in
cultured cells was analyzed by t test. Values of P<0.05
were considered statistically significant.
Results
Clinical data and histologic changes in patients
Clinical data in patients with MGA or IgAN are listed in
Table 1. There were no significant differences between
MGA and IgAN patients for age, follow-up term from onset
of urinary abnormalities, blood pressure, serum creatinine,
and creatinine clearance at the time of biopsy. Mean urine
protein excretion was significantly higher in IgAN patients
than that in MGA patients (P<0.01). The extent of
glomerular cellularity, ECM accumulation, and tubulointer-
stitial changes were semiquantified in both patient groups
and are shown in Fig. 1. The glomerular cell number and
GS score were significantly higher in IgAN patients
compared with those in MGA patients (MGA vs IgAN;
mean cell number: 66.1 vs 77.9, P<0.05; mean GS score:
0.73 vs 1.58, P<0.01). Tubular atrophy and interstitial
broadening were faintly present in IgAN patients but not in
MGA patients. However, there was no significant difference
in tubulointerstitial score change between the two groups
(mean score: 0.00 in MGA vs 0.26 in IgAN, P=0.188).
Fig. 1 The scorings of glomerular cell number (a), glomerulosclerosis
(b), and tubulointerstitial changes (c) in the biopsies. Glomerular cell
count and glomerulosclerotic indexes except tubulointerstitial changes
significantly increased in immunoglobulin A nephropathy (IgAN) (■)
compared with minor glomerular abnormalities (MGA) (□). *P<0.05
vs MGA; †P<0.01 vs MGA
1260 Pediatr Nephrol (2008) 23:1257–1267Expression of RAS components, TGF-β, and α-SM actin
in patients with MGA or IgAN
The glomerular localization of RAS components was
studied by immunohistochemistry in renal biopsies from
patients with either IgAN or MGA. Immunostaining of
AGT was detected mainly in proximal tubules and weakly
in GEC lining capillary walls in MGA specimens, as in
normal tissues (Fig. 2a). This renal localization of AGTwas
consistent with rat renal localization of AGT, as previously
described [33]. Of note, the staining level of AGT was
enhanced in a typical endocapillary pattern, including
changes of GEC and MC in IgAN patients (Fig. 2b). No
positive immunostaining of AGT was seen when a chicken
antibody against AGT, absorbed by preincubation with
excess human purified AGT, was used as the primary
antibody or when the primary antibody was omitted
(Fig. 2c). The double immunostaining in IgAN showed
that AGT was primarily detected on GEC, to a lesser extent
on MC, and only faintly on podocytes, supporting the
glomerular localization of AGT in an immunoperoxidase
technique (Fig. 2d–l).
ACE and ang II expression were examined by immuno-
fluorescence, as specific staining was not detected by the
immunoperoxidase technique. Faint immunofluorescence
of ACE and ang II was observed in glomeruli from patients
with MGA, as in normal tissues (Fig. 3a,c). In IgAN
patients, staining for ACE tended to increase in an
endocapillary pattern, but that of ang II was enhanced in
GEC and MC of nephritic glomeruli (Fig. 3b,d). A similar
staining level of AT1R was found in glomeruli, particularly
MC, in specimens from patients with MGA or IgAN, and in
control kidney tissues (Fig. 3e,f).
A semiquantitative analysis of glomerular staining for
AGT, ACE, ang II, and AT1R revealed that the level of
glomerular AGT (mean score 1.89) and ang II (mean score
Fig. 2 Glomerular expression
of angiotensinogen (AGT)
and its localization in the
biopsies. Kidney sections were
immunostained with anti-AGT
antibody in patients with minor
glomerular abnormalities
(MGA) (a) or immunoglobulin
A nephropathy (IgAN)
(b) (original magnification ×
200). Positive immunostaining
of AGT could not be detected
when a chicken antibody against
AGT, absorbed by preincubation
with excess human purified
AGT, was used as the primary
antibody (c). To identify
glomerular localization of AGT,
double immunofluorescence
staining of AGT (green; d, g, j)
with either glomerular endothe-
lial cells (GEC) marker CD31
(red; e), activated mesangial
cells (MC) (red; h), or podocyte
marker (red; k) in IgAN was
performed. Merged images
show that AGT clearly
colocalized on GEC (f), weakly
on activated MC (i), and only
faintly on podocyte (l)i n
IgAN (×400)
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enhanced in the IgAN group compared with the MGA
group (mean scores for AGT, ang II, ACE 0.93, 1.00, 0.50,
respectively) (P<0.01) (Fig. 4). The expression level of
AT1R tended to be lower, but not statistically significant, in
patients with IgAN compared with the MGA group (mean
score 1.63 in MGA vs 1.26 in IgAN).
The expression of TGF-β and α-SM actin, potential
factors associated with GN progression, was greatly
enhanced in the expanded mesangial regions in patients
with IgAN in contrast with patients with MGA (Fig. 5a–d).
Semiquantitative analysis indicated that the levels of TGF-
β and α-SM actin expression were significantly higher in
the IgAN group than in the MGA group (mean score 0.50
and 0.63 in MGA vs 1.91 and 1.91 in IgAN; P<0.01)
(Fig. 5e).
Correlation of RAS components with pathologic changes
in patients with MGA or IgAN
Possible relationships between glomerular RAS activation
and injury in diseased kidney were investigated to examine
the correlations between the expression of RAS components,
ang II-inducible factors, TGF-β and α-SM actin histologic
Fig. 3 Glomerular expression of components of the renin-angiotensin
system (RAS) in the biopsies. Kidney sections were immunostained
with either anti-angiotensin-converting enzyme antibody (a, b), anti-
angiotensin II antibody (c, d) or anti-angiotensin II type 1 receptor
antibody (e, f) in patients with minor glomerular abnormalities (MGA)
(a, c, e) or immunoglobulin A nephropathy (IgAN) (b, d, f) (original
magnification, ×200)
Fig. 4 Semiquantitative assessment of immunostaining of angiotensi-
nogen (AGT), angiotensin-converting enzyme (ACE), angiotensin II
(ang II) and ang II type 1 receptor (AT1R) in the kidney sections from
patients with minor glomerular abnormalities (MGA) (□) or immuno-
globulin A nephropathy (IgAN) (■). Data are means ± standard
deviation. †P<0.01 vs MGA
Fig. 5 Glomerular expression of transforming growth factor-β (TGF-
β) and α-smooth-muscle (α-SM) actin in biopsies. Kidney sections
were immunostained with either anti-TGF-β antibody (a, b)o rα-SM
actin (c, d) in patients with minor glomerular abnormalities (MGA) (a,
c) or immunoglobulin A nephropathy (IgAN) (b, d) (original
magnification ×200). Semiquantitative assessment of immunofluores-
cence staining of TGF-β and α-SM actin immunostaining in patients
with MGA (□) or IgAN (■). †P<0.01vs MGA
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patients with MGA or IgAN (Fig. 6). The glomerular AGT
expression was positively correlated with ang II (r=+0.711,
P<0.001) (Fig. 6a), TGF-β (r=+0.723, P<0.001) (Fig. 6b),
α-SM actin (r=+0.565, P<0.005) (Fig. 6c), glomerular
cell number (r=+0.542, P<0.005) (Fig. 6d), GS score
(r=+0.768, P<0.001) (Fig. 6e), and proteinuria (r=+0.436,
P<0.05) (Fig. 6f). Similarly, glomerular ang II level
showed a significant positive correlation with that of
TGF-β (r=+0.782, P<0.001) (Fig. 6g), α-SM actin
(r=+0.640, P<0.001) (Fig. 6h), cell number (r=+0.441,
P<0.05) (Fig. 6i), GS score (r=0.826, P<0.001) (Fig. 6j),
and proteinuria (r=+0.364, P<0.05) (Fig. 6k). However,
neither AGT nor ang II showed a significant correlation
with expression of ACE, AT1R, and hematuria index.
Finally, a positive correlation was demonstrated between
TGF-β and α-SM actin (r=+0.625, P<0.001) (Fig. 6l).
Effect of ang II on the AGT mRNA and protein levels
by human GEC
The regulation of AGT expression by GEC and a possible
role of GEC-AGT in disease progression of IgAN were
examined using cultured human GEC. The addition of
10
−7 M ang II rapidly induced AGT mRNA expression of
quiescent human GEC after stimulation for 1 h. This
increase peaked at 3 h, with a sevenfold increase, and then
gradually decreased during the course of the experiment
(Fig. 7a). When the response of AGT transcript to ang II
dose was investigated after incubation for 3 h, a dose-
dependent increase between 10
−11 and 10
−7 M was seen
(Fig. 7b). Western blot analysis revealed a time-dependent
increase of AGT protein product to 10
−7 Ma n gI I
stimulation. The increased expression of AGT protein
followed the increase of AGT mRNA by GEC and peaked
Fig. 6 Plots of correlations between the staining levels of angio-
tensinogen(AGT)andangiotensinII(angII)(a), AGTand transforming
growth factor-β (TGF-β)( b), AGT and α-smooth-muscle (α-SM)
actin (c), AGT and glomerular cell number (cell number) (d), AGT and
glomerulosclerosis (GS) score (e), AGT and proteinuria (f), ang II and
TGF-β (g), ang II and α-SM actin (h), ang II and cell number (i), ang
II and GS score (j), ang II and proteinuria (k), and TGF-β and α-SM
actin (l) in patients with minor glomerular abnormalities (MGA) (○)o r
immunoglobulin A nephropathy (IgAN) (•) (correlation; P value) The
levels of AGT positively correlate with the level of ang II (r=+0.711;
P<0.001), TGF-β (r=+0.723; P<0.001), cell number (r=+0.542; P<
0.005), GS score (r=+0.768; P<0.001), and proteinuria (r=+0.436;
P<0.05). Ang II is also positively correlated with TGF-β (r=+0.782;
P<0.001), α-SM actin (r=+0.640; P<0.001), cell number (r=+
0.441; P<0.05), GS score (r=+0.826; P<0.001), and proteinuria (r=
+0.364; P<0.05). The levels of TGF-β positively correlate with the
level of α-SM actin (r=+0.625; P<0.001)
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the results of RT-PCR analysis, a dose-dependent increase
of human GEC-AGT protein to ang II stimulation was
observed between 10
−11 M and 10
−7 M (Fig. 8b).
Discussion
Enhanced intrarenal RAS has been implicated in the
development of hypertension and the progression of
chronic renal diseases, including IgAN [1, 2, 17]. Ang II,
the major effector molecule of the RAS cascade, is a key
mediator of glomerular hypertension as well as glomerular
sclerosis through the induction of TGF-β [5, 6]. However,
glomerular expression of RAS components and their
association with local RAS activity and injury has not been
extensively studied in human subjects, especially pediatric
patients with IgAN.
In this study, we demonstrated for the first time that both
glomerular expression of AGT protein, a sole substrate for
RAS cascade, and ang II were strikingly increased with
GEC and MC in nephritic glomeruli of pediatric IgAN. As
it is already known that ang II is locally produced within
the glomerulus and RAS is present in glomerular cell types
such as GEC, MC, and podocyte [19, 20, 34], the increased
expression of ang II seen in pediatric IgAN most likely
reflects enhanced glomerular RAS activation under this
disease setting.
We also demonstrated that there was a positive correlation
between levels of glomerular AGT, ang II, and ang II-
inducible factors (TGF-β and α-SM actin) and glomerular
injury (cell proliferation and ECM accumulation), suggesting
that the activated glomerular RAS cascade contributes to the
development andprogressionofglomerularinjuryinpediatric
IgAN. There are several studies investigatingglomerulargene
expression of RAS components in IgAN [17, 24, 35, 36].
Most studies have shown an increased expression of renin,
AGT,a n dACE genes and decreased expression of AT1R
gene in nephritic glomeruli of IgAN. Furthermore, it has
been shown that a negative feedback loop exists between ang
II and its receptor, AT1R, in glomerular cells [36]. Therefore,
if there was a proportional increase in ang II as a result of
increased upstream components of RAS, a proportional Fig. 7 Effects of angiotensin II (ang II) on the expression of
angiotensinogen (AGT) messenger ribonucleic acid (mRNA) by
cultured human glomerular endothelial cells (GEC). Human GEC
were incubated with 10
−7 M ang II for the indicated time, extracted,
and analyzed for AGT mRNA levels by real-time polymerase chain
reaction (RT-PCR) (a). Values are means ± standard deviation (SD).
*P<0.05 and †P<0.01 vs time 0. Human GEC were incubated for 3
h with vehicle control or with indicated doses of ang II, extracted, and
analyzed for AGT mRNA levels by RT-PCR (b). The graph represents
the mean ± SD of at least three independent experiments. *P<0.05
and †P<0.01 vs control
Fig. 8 Effects of angiotensin II (ang II) on the expression of
angiotensinogen (AGT) protein by cultured human glomerular
endothelial cells (GEC). Human GEC were incubated with 10
−7 M
ang II for the indicated time, extracted, and then subjected to Western
blot analysis for AGT and β-actin (a). Western blot analysis
demonstrated two specific immunoreactive bands between 50 and
60 kD. Data for AGT protein levels were normalized by β-actin
protein levels. The graph represents the mean ± standard deviation
(SD) of at least three independent experiments. †P<0.01 vs time 0.
Human GEC were incubated for 12 h with vehicle control or with
indicated doses of ang II, extracted, and analyzed, as described in a
(b). Data are means ± SD of at least three independent experiments.
*P<0.05 vs control
1264 Pediatr Nephrol (2008) 23:1257–1267deactivation of AT1R expression in IgAN would be expected.
Here, we found a significantly greater expression of
glomerular AGT protein and ang II peptides and a tendency
for higher ACE protein levels and lower AT1R protein levels
in pediatric IgAN compared with MGA patients, indicating
that the glomerular AGT level may directly regulate the ang
II activity under the coordination of ACE and AT1R
expression and other ang II-producible enzyme activity.
Various enzymes, including cathepsin and chymase, are
involved in the RAS besides renin and ACE, which are
classical enzyme synthesizing ang II from AGT [37]. Indeed,
approximately 40% of the ang II found in the kidney is
generated by ACE-independent pathways [38]. In any case,
local levels of renin and ACE are not related to the synthesis
of ang II in situations where AGT levels are very high [18,
20, 21]. Thus, the quantity of AGT might well be the most
important element for the level of ang II production. Indeed,
recent experimental studies using rat models of nephropathy
indicated that enhanced intrarenal AGT expression is linked
to the increased level of ang II production and contributes to
the development of glomerular injury [20–22, 39].
We previously disclosed the mechanisms and the role
of ang II-induced ECM deposition through MC [5, 6]. Ang
II stimulates ECM synthesis through he induction of
TGF-β expression in cultured rat MC [5] and affects the
plasminogen activator/plasminogen activator inhibitor-1
system to result in accelerated deposition of ECM [6],
which indicates that ang II can act as a potent fibrotic
molecule independent of its effects on blood pressure. Ang
II can also induce MC activation (α-SM actin positive)
[39–42]. In addition, experimental and human studies have
shown that the degree of mesangial cellularity is associated
with a high sensitivity to beneficial effects of ACEi and ARB
on glomerular structure and proteinuria, suggesting that the
glomerular ang II level may contribute to proliferation of
MC [43]. Thus, our findings obtained here that the level of
glomerular ang II is associated with the levels of TGF-β
and α-SM actin expression as well as glomerular injury
characterized by cell proliferation and ECM accumulation
are consistent with the recent view of ang II action.
GEC damage and dysfunction are early features of many
types of GN [44, 45]. Injury to GEC induces the secretion
of various mediators, such as vasoactive substances, cyto-
kines, and growth factors critical in the regulation of
glomerular capillary tone and glomerular remodeling [19,
46–48]. Lee et al. demonstrated that GEC injury results in
increased AGT and TGF-β mRNA by GEC and MC in the
subtotal nephrectomized rat model, suggesting that acti-
vated or injured endothelial cells synthesize AGT, trigger-
ing a cascade of ang II, TGF-β, and ECM protein gene
expression with resultant development of the glomerular
sclerotic lesion [19]. Here we provide in vivo data showing
a striking increase of GEC-AGT and ang II in patients with
IgAN as well as in vitro data indicating the potential of
GEC to synthesize AGT protein and stimulatory effects of
ang II on GEC-AGT expression. Taken together, it seems
likely that GEC plays a crucial role in the activation of local
RAS, and self-amplifying properties of ang II production in
GEC are associated with the glomerular hemodynamic
changes and the development of progressive glomerular
injury in human GN.
In general, RAS inhibitors are commonly used by
chronic IgAN patients with hypertension or those with
heavy proteinuria or initial impairment of renal function.
We should stress that glomerular RAS activation could
occur in pediatric IgAN without heavy proteinuria, hyper-
tension, and renal impairment. IgAN patients in this study
had a short-term observation period from onset to time of
renal biopsy, renal lesions, characterized with mesangial
proliferative changes, low-grade interstitial fibrosis, and
tubular atrophy, indicating that they were diagnosed at an
early stage of IgAN [14, 49]. Thus, considering the
accumulating evidence that ang II plays a critical role in
MC activation as well as glomerular hemodynamic changes
and development of glomerulosclerosis, early treatment
with ACEi and/or ARB in pediatric IgAN, even in the
absence of hypertension and/or severe proteinuria, is
reasonable for preventing progression in IgAN.
In conclusion, our study showed that activated glomerular
AGT expression is likely to be involved in local RAS
activation, leading to enhanced local ang II production, in
pediatric IgAN with normal blood pressure and normal renal
function and, thereby, may trigger a dangerous RAS cascade
resulting in overproduction of TGF-β and progression of
glomerular injury. Moreover, a self-amplification loop of
GEC-AGT production with ang II stimulation seems to drive
the further injury of nephritic glomeruli in IgAN patients.
These data provide a rationale for early intervention with
RAS inhibitors in pediatric IgAN patients even in the
absence of hypertension and/or impairment of renal function
to prevent progression of glomerular injury.
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